News
Makary and Center for Biologics Evaluation and Research Director Vinay Prasad unveiled a new framework in the New England ...
FDA Commissioner Marty Makary reportedly initiated a brief request last week to decline approval of a rare disease drug ...
FDA Commissioner Marty Makary’s pledge to reexamine the safety of medication abortion isn’t just pointless — it’s dangerous.
All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...
While there's little disagreement that speeding drug approvals would be a good thing, there are more questions than answers ...
The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...
Speaking at BIO2025, rare disease leaders from Ultragenyx, Amylyx and Yale questioned the need for the new regulatory pathway ...
And offering a fast-track to approve drugs the Trump administration views as a priority. Welcome to the new Food and Drug ...
Qualifying manufacturers will be able to submit some data while clinical trials are ongoing. Marty Makary is the commissioner ...
FDA Commissioner Marty Makary said that one of his key priorities is to modernize the agency by streamlining the drug review ...
10d
Clinical Trials Arena on MSNFDA Commissioner envisions fewer delays, more clinical trial flexibility and AI useFDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.
An FDA pilot program, known as the Commissioner’s Priority Voucher program, could drastically change the way pharmaceutical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results